Cargando…

Pulmonary surfactant itself must be a strong defender against SARS-CoV-2

Pulmonary surfactant is considered to be one of the soaps. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the other enveloped viruses become very weak against surfactant. The SARS virus binds to angiotensin-converting enzyme (ACE2) receptor and causes pneumonia. In the lung, the AC...

Descripción completa

Detalles Bibliográficos
Autor principal:	Takano, Hideyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833517/ https://www.ncbi.nlm.nih.gov/pubmed/32590326 http://dx.doi.org/10.1016/j.mehy.2020.110020

Ejemplares similares

Defending against SARS-CoV-2: The T cell perspective
por: Almendro-Vázquez, Patricia, et al.
Publicado: (2023)

Cationic Surfactants as Disinfectants against SARS-CoV-2
por: Karamov, Eduard V., et al.
Publicado: (2022)

Hold Breath: Autonomic Neural Regulation of Innate Immunity to Defend Against SARS-CoV-2 Infection
por: Wang, Changle, et al.
Publicado: (2022)

Adsorption of Pulmonary and Exogeneous Surfactants on SARS-CoV-2 Spike Protein
por: Santo, Kolattukudy P., et al.
Publicado: (2023)

Training on Trial: How Workplace Learning Must Reinvent Itself to Remain Relevant
por: Kirkpatrick, James, et al.
Publicado: (2010)

COVID-19 pandemic: ten research questions Africa must answer for itself
por: Bonney, Evelyn Y, et al.
Publicado: (2020)

The Defenders of the Alveolus Succumb in COVID-19 Pneumonia to SARS-CoV-2, Necroptosis, Pyroptosis and Panoptosis
por: Schifanella, Luca, et al.
Publicado: (2022)

The Defenders of the Alveolus Succumb in COVID-19 Pneumonia to SARS-CoV-2 and Necroptosis, Pyroptosis, and PANoptosis
por: Schifanella, Luca, et al.
Publicado: (2023)

Postacute sequelae of SARS-CoV-2 infection. Osteonecrosis must not be overlooked
por: Koutalos, Antonios A., et al.
Publicado: (2022)

Antiseptic Polymer–Surfactant Complexes with Long-Lasting Activity against SARS-CoV-2
por: Molchanov, Vyacheslav S., et al.
Publicado: (2022)

SARS‐CoV‐2‐related polyradiculitis must be preceded by PCR‐confirmed COVID‐19
por: Finsterer, Josef
Publicado: (2023)

Neutrophils defending the defenders
por: Singh, Roli, et al.
Publicado: (2021)

Surfactants – Compounds for inactivation of SARS-CoV-2 and other enveloped viruses
por: Simon, Miriam, et al.
Publicado: (2021)

Confronting Covid-19 by exploring the possibility of vaccinating with live SARS-CoV-2 virus itself, via a route that would reduce the incidence of pulmonary complications
por: Joly, Etienne
Publicado: (2020)

Defending Against Catastrophic Terrorism
Publicado: (2006)

Before attributing subdural empyema to SARS-CoV-2—differential causes must be ruled out
por: Finsterer, Josef
Publicado: (2023)

To Defend or Not To Defend: That’s the Question
por: Varahan, Sriram, et al.
Publicado: (2016)

A House Divided against Itself
Publicado: (1896)

Does SARS-CoV-2 Bind to Human ACE2 More Strongly Than Does SARS-CoV?
por: Nguyen, Hoang Linh, et al.
Publicado: (2020)

SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself
por: Ferreira-Gomes, Marta, et al.
Publicado: (2021)

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021)

Circulating Exosomes Are Strongly Involved in SARS-CoV-2 Infection
por: Barberis, Elettra, et al.
Publicado: (2021)

The challenges of informative wastewater sampling for SARS-CoV-2 must be met: lessons from polio eradication
por: O'Reilly, Kathleen M, et al.
Publicado: (2020)

Ransomware: defending against digital extortion
por: Liska, Allan, et al.
Publicado: (2016)

Pulmonary immune responses against SARS-CoV-2 infection: harmful or not?
por: Guillon, A., et al.
Publicado: (2020)

Reduced DMPC and PMPC in lung surfactant promote SARS-CoV-2 infection in obesity
por: Du, Kang, et al.
Publicado: (2022)

Tailored lipopeptide surfactants as potentially effective drugs to treat SARS-CoV-2 infection
por: Biria, Davoud
Publicado: (2022)

Surfactant protein D (SP-D) as a biomarker of SARS-CoV-2 infection
por: Salvioni, Lucia, et al.
Publicado: (2022)

Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury
por: Cattel, Francesco, et al.
Publicado: (2021)

Emergence of SARS-CoV-2 through recombination and strong purifying selection
por: Li, Xiaojun, et al.
Publicado: (2020)

Pre-endoscopy SARS-CoV-2 testing strategy during COVID-19 pandemic: the care must go on
por: Casper, M., et al.
Publicado: (2022)

Before blaming SARS-CoV-2 vaccines for thalamic lacunar stroke, alternative etiologies must be ruled out
por: Finsterer, Josef
Publicado: (2023)

Before placental damage can be attributed to SARS-CoV-2, alternative causes must be sufficiently ruled out
por: Finsterer, Josef
Publicado: (2023)

“The climate itself must have hidden some medicines”: traditional veterinary medicine of indigenous and non-indigenous campesinos of the southern Andes
por: Olivares, Fernanda, et al.
Publicado: (2022)

Silver nanoparticles with excellent biocompatibility block pseudotyped SARS-CoV-2 in the presence of lung surfactant
por: Gupta, Govind, et al.
Publicado: (2022)

Coral Skeletons Defend against Ultraviolet Radiation
por: Reef, Ruth, et al.
Publicado: (2009)

Defending against smallpox: a focus on vaccines
por: Voigt, Emily A., et al.
Publicado: (2016)

Does Ceruloplasmin Defend Against Neurodegenerative Diseases?
por: Wang, Bo, et al.
Publicado: (2019)

PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV
por: Gai, Wei-wei, et al.
Publicado: (2011)

Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2
por: Bates, Timothy A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nhphb6bu9jkhe9nkc7c2md5hqn